Oct 05, 2016 11:01 am UTC| Business
The Phase II clinical study is intended to evaluate the efficacy and safety of YELIVA™ (ABC294640) in patients with advanced hepatocellular carcinoma (HCC), the most common primary malignant cancer of the liver with a...
Oct 05, 2016 11:01 am UTC| Business
The Phase II clinical study is intended to evaluate the efficacy and safety of YELIVA™ (ABC294640) in patients with advanced hepatocellular carcinoma (HCC), the most common primary malignant cancer of the liver with a...
Eze Software Group Ranked Among Top 100 FinTech Companies
Oct 05, 2016 11:01 am UTC| Business
BOSTON, Oct. 05, 2016 -- Eze Software Group, a premier provider of global investment technology, has been ranked among the top 100 financial technology companies in two prestigious industry surveys. Eze was ranked #52...
Eze Software Group Ranked Among Top 100 FinTech Companies
Oct 05, 2016 11:01 am UTC| Business
BOSTON, Oct. 05, 2016 -- Eze Software Group, a premier provider of global investment technology, has been ranked among the top 100 financial technology companies in two prestigious industry surveys. Eze was ranked #52...
Oct 05, 2016 11:01 am UTC| Business
NEW YORK, Oct. 05, 2016 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative...
Oct 05, 2016 11:01 am UTC| Business
NEW YORK, Oct. 05, 2016 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative...
Intellia Therapeutics to Present at Jefferies Gene Editing/Therapy Summit
Oct 05, 2016 11:00 am UTC| Business
CAMBRIDGE, Mass., Oct. 05, 2016 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA),a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that...